对抗性高血压的双内甲素抗剂阿布罗西坦 (PRECISION):多中心,盲定,并行组,第三阶段试验
Markus P Schlaich1, Marc Bellet2, Michael A Weber3
1Dobney Hypertension Centre, Royal Perth Hospital Research Foundation, Medical School, The University of Western Australia, Perth, WA, Australia; Department of Cardiology and Department of Nephrology, Royal Perth Hospital, Perth, WA, Australia.
一种新的双重内甲蛋白抗体,阿普罗西坦,有效降低了耐高血压患者的血压. 这项研究表明,阿普罗西坦
科学领域:
- 心血管医学
- 药理学
背景情况:
- 抗性高血压带来显著的心血管风险.
- 内甲蛋白通路与高血压病变有关,但缺乏向治疗方法.
- 研究了一种双重内甲蛋白抗剂,即阿普罗西坦,用于抗高血压.
研究的目的:
- 评估阿普罗西坦在耐高血压患者中降低血压的疗效.
- 评估阿普罗西坦在该患者群体中的安全性和耐受性.
主要方法:
- PRECISION试验是一项3期,多中心,随机,双盲,安慰剂控制的研究.
- 730名耐药高血压患者随机接受阿布罗西坦 (12.5 mg或25 mg) 或安慰剂治疗4周,随后进行32周的治疗期和12周的停药期.
- 主要终点:4 周内心压变化;关键次要终点:4 周内心压变化.
主要成果:
- 与安慰剂相比,阿普罗西坦在第4周显著降低了静脉压 - - 12. 5毫克的3. 8毫米升,25毫克的3. 7毫米升.
- 在戒断期后的第40周观察到持续的降血压效果.
- 最常见的不良反应是轻度至中度的胀或水分保留;整体耐受性良好.
结论:
- 在耐高血压患者中,阿普罗西坦在降低血压方面表现出比安慰剂更强的效果.
- 这种药物耐受性很好,并且在40周内显示持续作用.
- 艾普罗西坦是治疗耐药高血压的潜在新疗法.
更多相关视频
10:09Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
